Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a biotechnology company focused on discovering and developing aptamers, announced the successful completion of a Phase 1 study of its novel aptamer therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesion and aggregation of platelets by inhibiting the binding of von Willebrand Factor (vWF) to the GPIb receptor on platelets. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots. Archemix plans to develop ARC1779 as an anti-thrombotic drug for use in angioplasty and in a rare blood disorder that is mediated by vWF known as thrombotic thrombocytopenic purpura, or TTP.

Archemix plans to present a complete data set from this Phase 1 clinical trial within a peer-reviewed forum in 2007.

Based on the proof-of-mechanism data from this Phase 1 study, Archemix plans to commence a Phase 2 study of ARC1779 to evaluate the safety and efficacy of ARC1779 in acute coronary syndrome patients during the fourth quarter of 2007. Additionally, Archemix plans to initiate a Phase 1b study of ARC1779 in patients suffering from TTP in the fourth quarter of 2007. Approximately 3,000 new cases of TTP are diagnosed per year in the United States, but currently there is no approved drug therapy for the disease.

"We are very pleased to demonstrate ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart," said Jim Gilbert, M.D., Chief Medical Officer, Archemix. "In Phase 2, we hope to show that using ARC1779 during angioplasty may improve myocardial perfusion by reducing blood clots in the coronary microcirculation while also providing effective anti-thrombotic treatment at the primary site of arte rial blockage."

"We are developing a pipeline of aptamer therapeutics with a proprietary focus in acute cardiovascular and hematological diseases," commented Errol De Souza, Ph.D., President and Chief Executive Officer, Archemix. "The advancement of ARC1779 into Phase 2 will be a key milestone in the development of our broad product portfolio."

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company developing aptamers as a class of directed therapeutics for the prevention and treatment of human disease. The company is leveraging its proprietary drug discovery technology to fuel the growth of its development portfolio, which is primarily focused on acute cardiovascular and hematology diseases and cancer. Archemix's broad product pipeline, being developed both by the company as well as its licensees, includes multiple investigational compounds at various stages of development, several of which are moving into Phase 2 clinical trials. Archemix's lead proprietary product, ARC1779, a selective platelet inhibitor, is anticipated to start a Phase 2a and Phase 1b clinical trial before the end of 2007. Archemix' leadership position in intellectual property, technology and expertise relating to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., Elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences. For more information, please visit www.archemix.com.

Contact

Media
Yates and Associates
Kathryn Morris, Tel: 845-635-9828
or
Investor
Stern Investor Relations, Inc.
Lilian Stern, Tel: 212-362-1200
lilian@sternir.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... (APAC) breast cancer market will experience considerable expansion from $1.9 ... Compound Annual Growth Rate (CAGR) of 8.5%. --> ... states that the Asia-Pacific (APAC) breast ... 2014 to $3.4 billion by 2021, at a Compound Annual ...
(Date:2/11/2016)... -- Jeffrey Zucker , vice president of ... at this year,s Summit for Clinical Operations Executives (SCOPE), being ... Miami, FL. Zucker will discuss how sponsors can ... SCOPE,s "Improving Site Study Activation and Performance" portion of the ... at 11:05 a.m. --> --> ...
(Date:2/11/2016)... Fla. , Feb. 11, 2016 ... ) company providing high-quality specialty pharmacy care for ... announced today it has achieved full Specialty Pharmacy ... accrediting organization dedicated to promoting health care quality ... --> --> The URAC accreditation ...
Breaking Medicine Technology:
(Date:2/11/2016)... ISLAND, Australia (PRWEB) , ... February 11, 2016 ... ... full potential ?" motivational speaker, trainer and author Ray Clarke poses a question ... personal fulfillment . In his book, "Being in the Being" (published by ...
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... 11, 2016 , ... Talix today announced that Clive Fields, ... presenting at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 ... “ Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields ...
(Date:2/11/2016)... Washington, DC (PRWEB) , ... February 11, 2016 , ... ... positioning is based on evaluation of DataPoint’s team dedication and commitment to ... the companies comprising the annual list. The panel’s goal is to recognize and promote ...
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through ... Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. ... the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company ...
Breaking Medicine News(10 mins):